Advertisement

Topics

Pfizer objects to NICE methods in leukaemia drug rejection

07:09 EDT 21 Aug 2017 | pharmaphorum

NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the chance to receive a potentially curative bone marrow transplant. Experts said Besponsa (inotuzumab ozogamicin) could revolutionise mana...

Original Article: Pfizer objects to NICE methods in leukaemia drug rejection

NEXT ARTICLE

More From BioPortfolio on "Pfizer objects to NICE methods in leukaemia drug rejection"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...